DE69805002D1 - Kv2.1 antagonisten - Google Patents

Kv2.1 antagonisten

Info

Publication number
DE69805002D1
DE69805002D1 DE69805002T DE69805002T DE69805002D1 DE 69805002 D1 DE69805002 D1 DE 69805002D1 DE 69805002 T DE69805002 T DE 69805002T DE 69805002 T DE69805002 T DE 69805002T DE 69805002 D1 DE69805002 D1 DE 69805002D1
Authority
DE
Germany
Prior art keywords
antagonists
methods
assays
identifying
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69805002T
Other languages
English (en)
Other versions
DE69805002T2 (de
Inventor
Garrido Bubacz
David Dukes
Williams Mclean
Anderson Noe
James Peat
Ryszard Szewczyk
Andrew Thomson
Franklin Worley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE69805002D1 publication Critical patent/DE69805002D1/de
Application granted granted Critical
Publication of DE69805002T2 publication Critical patent/DE69805002T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69805002T 1997-12-18 1998-12-16 Kv2.1 antagonisten Expired - Fee Related DE69805002T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726630.8A GB9726630D0 (en) 1997-12-18 1997-12-18 Kv2.1 Antagonists
PCT/EP1998/008085 WO1999032487A1 (en) 1997-12-18 1998-12-16 Kv2.1 ANTAGONISTS

Publications (2)

Publication Number Publication Date
DE69805002D1 true DE69805002D1 (de) 2002-05-23
DE69805002T2 DE69805002T2 (de) 2002-11-21

Family

ID=10823738

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69805002T Expired - Fee Related DE69805002T2 (de) 1997-12-18 1998-12-16 Kv2.1 antagonisten

Country Status (9)

Country Link
US (1) US6589934B1 (de)
EP (1) EP1042322B1 (de)
JP (1) JP2001526289A (de)
AT (1) ATE216386T1 (de)
AU (1) AU1967199A (de)
DE (1) DE69805002T2 (de)
ES (1) ES2175842T3 (de)
GB (1) GB9726630D0 (de)
WO (1) WO1999032487A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004538268A (ja) * 2001-06-01 2004-12-24 ニューロサーチ、アクティーゼルスカブ Ｃｎｓ−モジュレーターとしての新規ヘテロアリール−ジアザビシクロアルカン類
US20050045205A1 (en) * 2003-08-29 2005-03-03 Stach Steven R. Apparatus and method for cleaning printed circuit boards
US20100059084A1 (en) * 2008-09-10 2010-03-11 Austin American Technology Corporation Cleaning and testing ionic cleanliness of electronic assemblies
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
CN112294835B (zh) * 2019-11-15 2021-09-17 南通大学 LncRNA-266在制备诱导棕色脂肪细胞分化药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU184960B (en) 1981-07-20 1984-11-28 Richter Gedeon Vegyeszet Process for preparing new derivatives of 3,7-diazabicyclo/3.3.1/ nonane
US5158969A (en) 1991-08-21 1992-10-27 Neurosearch A/S Indole derivatives as potassium channel blockers
US5559009A (en) 1994-03-04 1996-09-24 The Regents Of The University Of California Voltage-gated potassium channel gene, KV1.7, vectors and host cells comprising the same, and recombinant methods of making potassium channel proteins
HUT75093A (en) 1995-01-20 1997-04-28 Richter Gedeon Vegyeszet New anti-radical pharmaceutical compositions and process for producing them
CA2236171A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity

Also Published As

Publication number Publication date
EP1042322B1 (de) 2002-04-17
ATE216386T1 (de) 2002-05-15
WO1999032487A1 (en) 1999-07-01
AU1967199A (en) 1999-07-12
GB9726630D0 (en) 1998-02-18
JP2001526289A (ja) 2001-12-18
US6589934B1 (en) 2003-07-08
EP1042322A1 (de) 2000-10-11
DE69805002T2 (de) 2002-11-21
ES2175842T3 (es) 2002-11-16

Similar Documents

Publication Publication Date Title
DE69626660D1 (en) 2-alkylpyrrolidine
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
HK1028417A1 (en) Cysteine rich receptors-train
GEP20105118B (en) Anti-vegf antibodies
BR0212080A (pt) composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1
BR9810654B8 (pt) mÉtodo de preparaÇço de um polipeptÍdeo, molÉculas de anticorpo e composiÇço.
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
GB9818916D0 (en) Use
HK1017264A1 (en) Use of substituted imidazolidin-2,4-diones as analgesics.
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DE50111331D1 (de) Neue verwendung von proteinhydrolysaten
MXPA02009380A (es) Composicion de tenido que contiene un compuesto de para-aminofenol o para-fenilendiamina sustituido por un radical silanico.
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
ZA200006080B (en) Human BMP-7 promoter and method for exploring bone-related substance by using the same.
EA199800867A1 (ru) Соединения тетрагидробетакарболина
ZA98755B (en) Substituted hydroxy-anilino derivatives of cyclobutane-3,4-diones.
ATE216386T1 (de) Kv2.1 antagonisten
EA199800753A1 (ru) Бензотиофены, составы их содержащие и способы с их использованием
EA200000520A1 (ru) 2-АРИЛ-3-АРОИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
AU5999199A (en) Novel antibodies, drugs containing these antibodies and methods for screening compounds by using these antibodies
PT929299E (pt) 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee